Clinical Trials Browser

Interventional × Pancreatic Neoplasms × durvalumab × Clear all

NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Phase 1 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Phase 1 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

NCT05411094 2026-05-29

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Suspended

Gastrointestinal

Pancreatic Neoplasms

NCT06094140 2026-05-06

NEO-IMPACT

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04705818 2026-03-06

CAIRE

Phase 2 Completed

GastrointestinalSarcoma

Tertiary Lymphoid Structures, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04257448 2025-09-30

SEPION

Phase 1/2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase 2 Active not recruiting

GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05927142 2025-02-25

DURIPANC

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03572400 2024-04-19

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Phase 2 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03376659 2024-02-05

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Phase 1/2 Terminated

8 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03611556 2023-10-03

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Phase 1/2 Completed

213 enrolled 42 charts

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT05327582 2022-04-14

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT02777710 2021-09-05

MEDIPLEX

Phase 1 Completed

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02311361 2021-04-20

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Phase 1/2 Completed

65 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03038477 2020-09-14

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02885727 2019-09-12

Panc-Durval+RT

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02734160 2019-08-05

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02868632 2019-04-05

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1/2 Completed

124 enrolled 17 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

NCT02669914 2018-11-06

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Phase 2 Terminated

4 enrolled 12 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms